Novo Nordisk’s partial phase out of a key insulin product in India may create a supply gap that competitors are ready to fill. Eris Pharma and its contract manufacturing partner Biocon Biologics could benefit as demand shifts and procurement patterns adjust. The move could trigger pricing and market share changes across India’s insulin landscape, with near-term opportunities for local players.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
